On August 4, Edwards Lifesciences rose 3.1% in regular trading, trading at $88.72/share, with turnover of $163 million. The rally was driven by a wave of analyst upgrades and price target increases following the company's better-than-expected second-quarter results.

UBS upgraded Edwards Lifesciences to Buy from Neutral on July 28, raising its price target to $110 from $90. Leerink Partners also upgraded the stock to Outperform from Market Perform, lifting its target to $101 from $87. Rothschild & Co Redburn raised its price target to $102 from $99, maintaining a Buy rating. RBC Capital Markets highlighted the company as competitively differentiated and positioned to sustain double-digit growth as product catalysts build through 2027.

On the fundamental side, Q2 adjusted EPS came in at $0.78, beating the consensus estimate of $0.74 by 5.4%, while revenue of $1.74 billion exceeded the $1.70 billion estimate, representing 13.7% year-over-year growth. The company reaffirmed full-year adjusted EPS guidance of $2.95 to $3.05. Additionally, the Health Care Equipment sector broadly strengthened, with Intuitive Surgical up 5.78% and Stryker up 4.07%, creating a positive linkage effect.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)